Dolofort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolofort

Quick Facts

Property Description
Active ingredient Ibuprofen
Form Oral Solid (Tablet) and Topical Semi-Solid (Gel)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of Pain, Inflammation, and Fever
Origin Synthetic Compound

What Type of Medicine is Dolofort?

Dolofort is a pharmacological product defined by its active ingredient, Ibuprofen, which is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Ibuprofen is a synthetic compound derived from propionic acid, distinguishing it chemically from steroidal compounds and simple analgesics. This classification is clinically recognized by major health organizations globally, supporting its use for pain and fever relief.

The active compound is typically supplied as a racemic mixture of its two enantiomers. As an NSAID, Dolofort is primarily known for providing systemic relief when taken orally and localized relief when applied topically, differentiating it from medicines restricted to a single route of administration.

General Purpose and Action of Dolofort

The general therapeutic purpose of Dolofort is to relieve discomfort associated with three core symptoms: pain, inflammation, and fever. It functions simultaneously as an analgesic, an antipyretic, and an anti-inflammatory agent. Its core mechanism involves reducing the body’s synthesis of prostaglandins, which are fatty acid compounds that mediate these symptoms. For instance, the medicine is typically used to manage discomfort resulting from common inflammatory conditions. This dual action capability is supported by extensive pharmacological studies on the NSAID class, confirming its utility in reducing both the sensation of pain and the physical signs of swelling.

Dosage Forms and Preparation Type

Dolofort is a single-ingredient product, containing only Ibuprofen as the pharmacologically active substance. The product is available in distinct high-level dosage forms, specifically an oral solid form (Tablet) for systemic absorption and a topical semi-solid form (Gel) for application directly to the skin. The topical gel preparation offers a key differentiating feature, allowing for dermal application to achieve localized therapeutic concentrations in musculoskeletal tissue while minimizing systemic exposure, unlike the oral tablet form.

What side effects are possible with Dolofort?

Possible side effects and safety information

Official regulatory documentation structures the safety profile of Dolofort (Ibuprofen) by classifying documented adverse reactions based on their frequency and the body system affected (System-Organ Class or SOC).

Common adverse reactions reported in official prescribing information typically involve the Gastrointestinal system, including dyspepsia, nausea, vomiting, diarrhoea, and abdominal pain. Reactions affecting the Nervous system, such as headache and dizziness, are also frequently listed.

Serious adverse reactions are explicitly documented as class risks for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and require specific awareness. These include the potential for serious gastrointestinal bleeding, ulceration, and perforation, which can occur without warning symptoms, and an increased risk of serious cardiovascular thrombotic events (such as myocardial infarction or stroke).

Safety profiles address specific groups. Older adults are documented to have an increased risk, particularly for severe gastrointestinal complications. Use is contraindicated during the third trimester of pregnancy due to official concerns regarding fetal risk. Furthermore, regulatory labels state that the risk of certain serious events, notably cardiovascular and gastrointestinal complications, is linked to longer duration of use and higher doses.

Adverse Event Classification Examples of Officially Documented Risks
Common Dyspepsia, headache, dizziness, nausea
Serious Adverse Reactions GI bleeding/perforation, myocardial infarction, stroke, severe allergic reactions
SOC Groups Affected Gastrointestinal, Nervous System, Cardiovascular, Renal, Dermatological

The official safety structure mandates awareness of these potential risks without providing clinical advice or recommendations.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Dolofort (Ibuprofen) is officially documented as presenting with a range of clinical signs, most commonly involving the gastrointestinal and central nervous systems. Documented manifestations include nausea, vomiting, epigastric pain, headache, drowsiness, lethargy, dizziness, and confusion. More severe clinical presentations may involve unsteadiness, ringing in the ears (tinnitus), and low blood pressure (hypotension).

Regulatory sources classify certain outcomes as severe or life-threatening. These can include acute renal failure, metabolic acidosis, seizures, and a decreased level of consciousness leading to coma. Critical outcomes also involve serious gastrointestinal events such as ulceration, bleeding, and perforation, which have been officially documented as potentially fatal.

Official regulatory guidance mandates that immediate medical attention must be sought in all cases of suspected overdose. It is required to contact a Poison Control Center or emergency services right away, particularly if symptoms of severe toxicity—such as signs of stomach bleeding (bloody or black stools), trouble breathing, or inability to awaken—are observed.

Regulatory labeling states that no specific antidote is known for Ibuprofen overdose. Management is therefore symptomatic and supportive, involving procedures like activated charcoal administration and continuous monitoring of vital signs and renal function in a hospital setting. Population-specific notes include an increased risk of severity in the elderly and in dehydrated children.

Therapeutic Uses of Dolofort

What Dolofort Treats: Main Uses and Benefits

Dolofort is commonly used across conditions presenting with acute episodes and contributes to easing the overall symptom load of symptoms related to physical discomfort and systemic imbalance. Ibuprofen is relevant in contexts involving heightened systemic burden and is used for managing symptoms related to pain, inflammatory states, and systemic imbalance. This may help patients cope more steadily with symptom fluctuations during acute phases.

The medication is commonly used to help with a wide range of symptomatic conditions, including headache, general muscle aches, dental discomfort, backache, menstrual cramps (primary dysmenorrhea), and high body temperature associated with colds and flu. It is generally used across conditions involving inflammatory or irritative processes, such as arthritis or pain following minor injuries like sprains and strains.

“Applied in scenarios where additional management of discomfort is required, the medication assists in reducing symptoms that create noticeable physiological strain.”

The medication may assist with maintaining functional stability by easing symptoms that can interfere with daily functioning and general comfort during symptomatic periods.


Quick Fact: Relevant for Acute Symptom Management

Symptom Cluster Typical Contexts of Use Primary Patient Benefit
Pain, Fever, and Inflammation Acute illness, minor injuries, episodic pain, and chronic inflammatory conditions Contributes to easing the overall symptom load and distress

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Dolofort?

Dolofort (Ibuprofen) is subject to strict regulatory criteria that define who can and cannot use the medicine, based on government-approved labeling.

Absolute Contraindications

Use is contraindicated for patients with known hypersensitivity or allergic-type reactions (such as asthma) to any Nonsteroidal Anti-Inflammatory Drug (NSAID), including aspirin, or to any component of the medicine. It is strictly prohibited for those with a history of gastrointestinal bleeding or perforation or with active peptic ulceration. Patients with severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure are also excluded. Use is forbidden for treating pain right before or after Coronary Artery Bypass Graft (CABG) surgery.

Restricted Populations and Conditions

Conditional use is required for older adults (age 60 or older) and patients with mild to moderate renal or hepatic impairment, who must use the lowest effective dose for the shortest possible duration. High doses (2400 mg/day or greater) are generally avoided in patients with established cardiovascular disease. Use is not recommended for women who are actively attempting to conceive due to potential reversible effects on fertility.

Age-Group and Pregnancy Rules

The medicine is contraindicated during the third trimester of pregnancy. Most over-the-counter oral formulations are not for use in children under 12 years of age, with specific lower age or weight thresholds defined for specialized pediatric products.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several high-level interaction patterns for Ibuprofen (Dolofort), primarily involving pharmacokinetic and pharmacodynamic effects.

Contraindicated Combinations

Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, is contraindicated due to the increased risk of severe gastrointestinal adverse events. Use is also restricted for peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Interactions

Interacting Class/Substance Official Interaction Outcome Mechanism Classification
Anticoagulants (e.g., Warfarin) Enhanced effect, increasing the risk of severe bleeding and hemorrhage. Pharmacodynamic
Methotrexate & Lithium Increased plasma concentrations due to reduced renal clearance, raising toxicity risk. Pharmacokinetic
Antihypertensives (Diuretics, ACE Inhibitors) Diminished natriuretic or anti-hypertensive effect of the co-administered drug. Pharmacodynamic
Oral Corticosteroids & SSRIs Increased risk of gastrointestinal bleeding and ulceration. Pharmacodynamic

Timing and Substance Constraints

Ibuprofen may competitively inhibit the anti-platelet effect of low-dose Aspirin (le 75 mg/day); regulatory labeling suggests administering low-dose Aspirin at least 2 hours before Ibuprofen. Furthermore, Alcohol consumption increases the documented risk of stomach bleeding, while taking the oral form with food can reduce the maximum plasma concentration.

Mechanism of Action

Molecular Mechanism: COX Enzyme Inhibition

Dolofort's core mechanism involves the reversible, non-selective competitive inhibition of both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This fundamental molecular interaction blocks the primary step in the Arachidonic Acid Cascade, preventing the body's synthesis of prostaglandins and other related mediators that drive the body's defensive responses.

Pathway Modulation: Attenuating Prostanoid-Mediated Signaling

The resulting reduction in prostaglandin concentration modulates prostaglandin-mediated physiological responses. At the tissue level, decreased prostaglandin availability limits vasodilation (blood vessel widening) and subsequent leakage of fluid, which are precursors to tissue swelling. This action targets the humoral mediators involved in the body's defensive response.

Systemic Consequence: Thermoregulatory Resetting

The mechanism also involves a crucial central effect: the reduction of Prostaglandin E2 (PGE2) concentration within the hypothalamus. This CNS action actively resets the elevated thermal set-point, allowing the body to initiate heat-loss mechanisms (like sweating and peripheral vasodilation) to reduce core body temperature. These core changes characterize the drug's activity at the biological level.

Dosage and Administration Information

How to Use Dolofort: Official Administration Guidelines

Dolofort (Ibuprofen) administration is officially defined by its route and required dosage limits, differentiating between systemic and localized application patterns. The medicine is approved for Oral use (tablets/capsules) and Topical/Dermal use (gel).

Official Dosing and Frequency

Administration frequency and dosage are strictly regulated by the intended use and must not exceed defined daily maximums.

Feature Oral Administration Guideline Topical Administration Guideline
Standard Frequency Every 4 to 6 hours as needed (acute) or divided doses 3 to 4 times daily (chronic). Application limited to 3 to 4 times in a 24-hour period.
Maximum Dose Prescription use maximum is 3200 mg per 24 hours. Non-prescription use maximum is 1200 mg per 24 hours. Must not exceed approximately 10 grams of 5% gel in 24 hours.

Administration Context and Adjustments

Official instructions stipulate that the smallest effective dose must be used for the shortest duration necessary across all applications. The timing of administration can be adjusted based on tolerance; the oral form may be taken with food or milk if gastrointestinal discomfort occurs, as this does not substantially affect the total absorption amount.

For pediatric oral use, the dose is officially weight-based (e.g., 5 to 10 mg/kg per dose) and requires specific calculation. Topical gel use is generally restricted to older children and adults. The topical preparation requires the gel to be gently massaged into the skin and must not be covered with occlusive dressings.

Recent Clinical Evidence

Research evidence / Overview of studies for Dolofort

Evidence for Acute Pain and Symptom Management

Research related to outcomes in physical discomfort has been evaluated through Randomized Controlled Trials (RCTs) and meta-analyses. These studies primarily focused on populations of Adults experiencing acute and episodic manifestations, such as pain following dental procedures, headaches, or muscle aches. Researchers used study designs exploring how symptoms change over time, measuring outcomes related to systemic or functional imbalance, including how studies monitored timeframes for perceived comfort changes and collected overall assessments of pain outcomes.

Studies conducted during periods of increased symptom activity reported that the measured changes in pain intensity were described in the study populations. Some trials also described measurements that explored the effects of higher administration levels. Studies examined data patterns related to what is known as a ceiling effect, where measurements suggested that pain reduction did not consistently increase beyond certain levels of administration.

Studies related to primary dysmenorrhea (menstrual cramps) specifically include various RCTs and systematic reviews. These studies monitored patient-reported outcomes describing perceived discomfort and the ability to maintain daily functioning. Findings describe patterns observed in these studies, and research explored outcomes related to acute changes in comfort. However, data for certain groups remain insufficient, as research primarily explored short-term symptom changes, and follow-up durations were limited to a few menstrual cycles.


Evidence for Antipyresis (Fever Reduction)

Research examining the medicine’s use for outcomes related to systemic imbalance, such as high body temperature (fever), primarily involves Randomized Controlled Trials (RCTs). These trials were often comparative, with studies exploring its measured effects against other common fever-reducing compounds. The populations evaluated have included both adults and Pediatric patients.

In these studies conducted during periods of increased symptom activity, the research described patterns in the changes in body temperature outcomes measured. Studies monitored outcomes such as the magnitude of the measured temperature change and the total time the temperature was measured as lower. Findings indicate that the medicine was evaluated in research examining temporary physiological imbalance. Evidence contributes to understanding symptom patterns across various contexts involving fluctuating or unstable symptoms.

What remains uncertain is a lack of standardization across some clinical trials. While research is widespread, evidence quality varies across studies, and some formal systematic comparisons are complicated by variability in study methodologies and population definitions among trials.


Evidence for Chronic Inflammatory Conditions

Research exploring the use of this medicine in chronic inflammatory conditions and conditions marked by functional limitations, such as osteoarthritis and rheumatoid disorders, relies on both formal Clinical Trials and long-term Observational Studies. Studies monitored outcomes reflecting daily functioning or activity level, including patient-reported outcomes describing perceived discomfort and functional status.

Regulatory data and observational research described patterns where long-term systemic administration, especially at higher-level doses, was associated with research findings that prompted specific regulatory monitoring.


Evidence for Localized Pain Relief (Topical Gel)

The topical gel form of Dolofort was studied for outcomes related to physical discomfort in conditions associated with acute or disruptive episodes, such as minor sprains or localized joint pain. These studies primarily consisted of Randomized Controlled Trials (RCTs) where the gel was compared to a non-active vehicle. The research examined a pattern of localized delivery for achieving specific concentration levels in the tissue with simultaneous minimal systemic exposure.


Long-term Research and Follow-up

For all indications, the long-term effects are not fully established. Research examined short-term symptom changes. However, in chronic observational settings, data suggest patterns related to specific health outcomes that prompted regulatory monitoring. There is limited information for long-term outcomes, and research is ongoing.


Research Gaps and Uncertainties

The specific implications of the ceiling effect identified in some acute pain studies, and the full clinical consequences of continuous, high-dose use remain active areas of regulatory and scientific review. Comparative evidence among different administration schedules is also an area where more research is needed to refine the understanding of symptom patterns.

Frequently Asked Questions (FAQ)

Common questions about Dolofort (FAQ)

Q: What is the difference between Dolofort and other common medications for similar conditions?

Dolofort is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification reflects its action as an analgesic, antipyretic, and anti-inflammatory agent. Other common medications used for similar symptoms, such as acetaminophen (paracetamol), belong to different pharmacological classes and operate through distinct mechanisms.

Q: Does Dolofort stay in the body for a long time?

According to official product information, Dolofort is known to be rapidly absorbed following oral administration, with its peak concentration typically occurring within one to two hours. The medicine is then eliminated from the body relatively quickly after it has performed its intended function in relieving symptoms.

Q: What if I'm already taking blood pressure medication and want to use Dolofort?

Official labeling describes that Dolofort may reduce the blood pressure-lowering effect of certain medicines, such as ACE inhibitors or diuretics. Regulatory documents describe that close monitoring of blood pressure may be considered when these types of medicines are taken together.

Q: Does Dolofort interact with blood thinners?

Yes, regulatory documents warn about a potential interaction. Taking Dolofort with blood thinners (anticoagulants) may significantly enhance the blood thinner’s effect. This interaction can increase the documented risk of serious bleeding events.

Q: Can Dolofort be used during pregnancy?

Dolofort is strictly contraindicated (not allowed) during the third trimester of pregnancy due to documented risks to the fetus. For the first and second trimesters, use is generally restricted, and a discussion with a healthcare professional regarding the potential risks and benefits is noted.

Q: Does taking Dolofort affect the results of any common laboratory tests?

Abnormal results in certain laboratory tests, particularly those monitoring liver function, have been described in regulatory documents as potential rare side effects of the medicine. If liver issues develop, changes in laboratory test results may be seen.

Q: Can Dolofort be purchased without a prescription?

Dolofort is generally available over-the-counter (OTC) in lower strengths for non-prescription use. However, official information confirms that higher-strength formulations are typically restricted and are only available with a prescription.

Q: How quickly is Dolofort expected to start working?

Following oral administration, the medicine is rapidly absorbed into the system. Official patient information indicates that symptomatic relief typically begins to be felt within 30 to 60 minutes after taking the dose.

Q: Is it common to feel tired while taking Dolofort?

While fatigue or tiredness is not listed as a common reaction, regulatory documentation mentions nervous system effects such as sleepiness, dizziness, or unusual drowsiness. these side effects have been reported in the post-marketing or clinical trial setting.

Q: Is there a maximum time someone can stay on Dolofort?

Non-prescription (OTC) use is generally limited to up to 10 days for pain relief or up to 3 days for fever reduction, unless determined necessary by a healthcare professional. The risk of serious adverse events, particularly heart and stomach problems, increases with longer duration of use.

Q: Can people with kidney issues use Dolofort?

Use is strictly contraindicated (not allowed) in patients with severe renal (kidney) failure. Official warnings state that patients with existing impaired renal function are at increased risk for kidney-related side effects and are advised to use the medication with caution, which often involves use of the lowest possible strength.

Q: Is Dolofort appropriate for people with liver conditions?

Use is contraindicated in patients with severe hepatic (liver) failure. If a patient has signs of liver dysfunction, official guidance is that the medicine should be discontinued, as rare cases of severe hepatic reactions have been reported.

Q: What is the risk of an allergic reaction to Dolofort?

Allergic-type reactions, including severe ones such as anaphylaxis (a potentially life-threatening reaction), are possible with this medicine. For this reason, use is contraindicated for anyone with a known hypersensitivity or history of asthma or allergy to NSAIDs.

Q: Are there any long-term effects of using Dolofort for a long period?

Regulatory documents state that the risks of serious adverse events are increased with long-term systemic use. These risks include serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal bleeding.

Q: Is Dolofort safe for children or teenagers?

The medicine is generally not for use in children under 12 years of age in over-the-counter oral tablet forms. Specialized pediatric liquid formulations are available for younger children, and administration is typically weight-based and requires a healthcare professional's guidance.

Q: Can Dolofort affect the ability to drive or operate machinery?

Side effects in the nervous system, such as dizziness, drowsiness, or visual disturbances, may occur while taking this medicine. Due to the potential for these side effects, activities requiring full mental alertness, such as driving or operating machinery, may need to be approached with caution.

Q: Are the studies on Dolofort published in medical journals?

Regulatory reviews and evidence summaries for Dolofort are based on formal research, including Randomized Controlled Trials (RCTs) and meta-analyses. These authoritative studies are typically published and subject to peer review in medical and scientific journals.

Q: What should be done if an unexpected symptom occurs while on Dolofort?

Official instructions advise that if any new or concerning symptoms appear, especially those indicating serious side effects like unexplained pain or bleeding, the use of the medicine should be stopped immediately. Contacting a healthcare professional for further evaluation is advised.

Q: Is there a different name for the active ingredient in Dolofort?

Yes, Dolofort contains the active ingredient Ibuprofen. Ibuprofen is the official generic name recognized globally by health authorities for this Nonsteroidal Anti-Inflammatory Drug (NSAID) and is used universally to refer to the compound.

Q: Is Dolofort meant to cure a condition or just manage symptoms?

Official product information describes Dolofort as a medicine used for the symptomatic relief of pain, inflammation, and fever. It functions by modifying the body’s response to these symptoms and is not intended to cure the underlying medical conditions that cause them.

Q: How does the listed 'maximum strength' of Dolofort relate to its effect?

Research has examined what is known as a ceiling effect for pain relief with this class of medicine. This effect suggested that pain reduction did not consistently increase beyond certain levels of administration, even if the maximum approved dose is higher than that level.

Q: Can I take other prescription medications at the same time as Dolofort?

Regulatory guidance states that a healthcare professional should be consulted before taking Dolofort with other prescription medications. This is important because many substances have known interactions with the NSAID class of medicine, which could alter their safety or effectiveness.

Q: How long does it take for Dolofort to be completely cleared from the system?

Official documents on elimination describe that Dolofort is cleared from the body relatively quickly. This clearance is measured using technical pharmacokinetic terms and ensures the medicine does not accumulate in the system with standard dosing.

Q: Does Dolofort have any black box warnings, and what do they mean?

Yes, official U.S. regulatory labels include prominent warnings (often called Black Box Warnings) for the entire NSAID class. These warnings highlight the potential for serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal bleeding.

Q: What is the difference between the intended benefits and potential risks of Dolofort?

Official safety reviews, conducted by health authorities, have concluded that the overall benefits of the medicine are considered to outweigh the potential risks. This conclusion is based on strict adherence to the official administration and dosing guidelines.

Q: Are there different versions of Dolofort available (e.g., liquid, tablet)?

Official product labeling confirms that, in addition to the oral tablet and topical gel, the medicine is available in several forms. These forms include liquid/suspension and chewable tablets, particularly for use in pediatric populations.

Q: Can Dolofort be used for chronic conditions or only short-term issues?

Dolofort is used for both short-term (acute) pain and fever relief, as well as for the management of symptoms associated with certain chronic inflammatory conditions. Long-term systemic administration, however, requires specific professional monitoring due to increased risks.

Q: Are there any known issues with Dolofort and eye or vision health?

Regulatory documentation on side effects mentions that visual disturbances, blurred vision, or other changes in vision have been reported as very rare side effects. If these vision changes occur, regulatory guidance notes that discontinuation of the medicine and seeking evaluation may be necessary.

Q: Does Dolofort have any known interactions with vaccines?

Evidence suggests that using this class of medicine after receiving a vaccination is generally acceptable for managing expected symptoms like fever or pain. However, using it prophylactically (before the vaccination) is generally restricted.

Q: What is the likelihood of experiencing a rare side effect from Dolofort?

The frequency of side effects is officially classified in regulatory documents. Those designated as rare typically occur in less than 1 in 1,000 patients, and those designated as very rare occur in less than 1 in 10,000 patients.

Q: Is there any evidence about Dolofort causing weight changes?

Official documents on side effects mention that fluid retention and edema (swelling) have been observed in some patients taking medicines from this class. This fluid retention can sometimes be associated with noticeable weight changes.

Q: What are the typical conditions or patient types that should avoid Dolofort?

Absolute contraindications include severe heart, kidney, or liver failure, active gastrointestinal bleeding or ulcers, and known hypersensitivity to NSAIDs. Caution is also required for restricted populations, such as older adults and those with mild to moderate kidney or liver impairment.

Q: Does the time of day matter when taking Dolofort?

While the dose frequency is defined, the specific time of day is generally flexible. The official administration context notes that the oral form may be taken with food or milk to help reduce the potential for stomach discomfort.

How should Dolofort be stored and disposed of?

How to Store and Dispose of Dolofort?

The official storage and disposal requirements for Dolofort (Ibuprofen) are strictly defined by regulatory documents to ensure stability and public safety.

Storage Requirements

Oral tablets typically require storage at Controlled Room Temperature (between 20 C and 25 C), while the topical gel should be stored below 25 C or not above 30 C.

All forms must be stored out of the sight and reach of children.

To maintain quality, the medicine should be kept in its original container, which should be tightly closed where applicable. Certain formulations require protection from light.

Disposal Instructions

Unused or expired product must not be disposed of via wastewater or household waste. Disposal should follow official protocols, such as drug take-back programs, or by adherence to local requirements for household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolofort found in:

A-Z Index: